An Interleukin-23 (IL-23) Antagonist for the Treatment of Moderate to Severely Active Crohn's Disease in Adults
Crohn's disease (CD) is a chronic, progressive, inflammatory bowel disease (IBD) that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The American Gastroenterological Association (AGA) treatment guidelines for moderate to severe Crohn's disease have been updated and new long-term goals for management of the disease have been established. There is a need for new treatment options, with a focus on long-term patient outcomes. An interleukin-23 (IL-23) antagonist was recently approved for the treatment of Crohn's disease. The objective of this webinar is to review the recently updated Crohn's disease treatment guidelines, the long-term treatment goals, and the pivotal trials program for the recently approved IL-23 antagonist.
Learning Objectives:
- Discuss the clinical burden of CD
- Review the AGA Guidelines for Medical Management of Moderate to Severe CD
- Review the Treat-to-Target approach from the STRIDE-II guidelines
- Review the efficacy and safety data of an IL-23 antagonist in patients with moderate to severely active Crohn's disease in adults from the phase 3 pivotal trials program
Speaker:
Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Director of the Inflammatory Bowel Disease Center
Co-director of the Advanced IBD Fellowship Program at the University of Chicago Medicine
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenter are those of the sponsor or presenter and not of AMCP.
Sponsored by:
AbbVie US Medical Affairs
For individuals from the media/press who are interested in attending, please email @email.
